Claire Leurent PhD MBA is a venture capital investor with operational experience in leading drug development from scientific discovery to registration studies enabling regulatory approval application. She is passionate about science and people and highly motivated by the opportunity to deploy transformative technologies and business models to generate progress in the community.
Claire earned her PhD in molecular and cellular biology at the Institute of Genetics, Molecular and Cellular Biology (IGBMC) in Strasbourg Illkirch-Graffenstaden, France in 2002. She then worked in drug development in several capacities for 14 years. She started as a Project Manager in a First in Human clinical center at Forenap Pharma in Rouffach. She was then hired by Wyeth Pharmaceutical in Paris as a Senior Clinical Scientist to support global phase 3 registration trials, NDA dossier submission and new product launch for a variety of programs in Women's health and Neuroscience. In 2010, she relocated to the United States to join Pfizer Research and Development in Groton CT then in Cambridge MA, where she led teams in designing and conducting clinical plans from First in Human to Proof of Concept studies for small molecules, biologics and digital biomarker technologies. Over the years, she developed a passion for the business aspects of innovation, which led her to join the Portfolio Enhancement team responsible for screening external opportunities for business development and to do an internship with Pfizer's Strategic Investment in 2015.
She received her Master of Business Administration from Massachusetts Institute Technology Sloan in June 2016 and then pivoted to corporate venture investment as a way to scale up and diversify the breadth of her technological reach and gain prime experience in virtually all stages of investments (Seed to PIPE/SPAC) in established corporate venture funds. She joined Samsung Venture America, the investment entity serving Samsung conglomerate, in 2017 with a focus on deploying capital in Life Science, Health Economics and Connected Health sectors. In 2019, she joined JJDC, the investment team serving Johnson & Johnson, with a focus on pharmaceutical areas across neurosciences, oncology, infectious diseases and vaccines, cardiovascular, renal diseases, ophthalmology, immunology, inflammation, and modalities encompassing small/large molecules, cell/gene therapy, RNA and RNA-targeting, AI/ML and quantum computing.